Case report: Eli Lilly loses latest Alimta battle

In the latest instalment of the long-running patent dispute between Actavis and Eli Lilly in relation to anti-cancer drug Alimta (pemetrexed disodium), in February 2016 Mr Justice Arnold at the English High Court handed down his judgment on the issues remitted to him by the English Court of Appeal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Accord’s generic hopes dashed in cyanide antidote ruling

14 October 2026 Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.

Pharma

Novo’s semaglutide protection weakens after European ruling

13 October 2026 Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.

Pharma

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

8 October 2026 Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.

More features

Haynes Boone expands in California with new office

Accord’s generic hopes dashed in cyanide antidote ruling

Novo’s semaglutide protection weakens after European ruling

UK to clamp down on non-compete clauses and long notice periods

Brazilian firm appoints patent strategist to lead department

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

MSD’s Keytruda hit by eight-country ban across Europe

WATCH: LEO Pharma head of IP rights on doing more with less

Case report: Eli Lilly loses latest Alimta battle

More on this story

Editor's picks

Editor's picks

More features